Advaxis, Inc. (NASDAQ:ADXS)’s share price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $0.76 and last traded at $0.79, with a volume of 8080 shares traded. The stock had previously closed at $0.80.
Separately, HC Wainwright restated a “buy” rating on shares of Advaxis in a report on Wednesday, September 12th.
The firm has a market capitalization of $49.66 million, a PE ratio of -0.34 and a beta of 1.82.
In related news, Director Roni Appel bought 33,333 shares of Advaxis stock in a transaction on Tuesday, September 11th. The shares were purchased at an average price of $1.20 per share, for a total transaction of $39,999.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.72% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the company. LMR Partners LLP bought a new position in shares of Advaxis during the 2nd quarter valued at about $171,000. Franklin Street Advisors Inc. NC bought a new position in shares of Advaxis during the 2nd quarter valued at about $190,000. Paloma Partners Management Co bought a new position in shares of Advaxis during the 2nd quarter valued at about $265,000. Finally, BlackRock Inc. lifted its holdings in shares of Advaxis by 28.2% during the 1st quarter. BlackRock Inc. now owns 2,925,417 shares of the biotechnology company’s stock valued at $4,943,000 after purchasing an additional 644,201 shares in the last quarter. Institutional investors and hedge funds own 21.50% of the company’s stock.
Advaxis Company Profile (NASDAQ:ADXS)
Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.
Featured Story: Do stock splits help investors?
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.